Key result
The RT-LAMP-coupled CRISPR–Cas12 assay yielded 96% sensitivity, 100% specificity, and 97% agreement for HCV RNA detection compared to the reference method.
Why the study?
Identifying individuals with current hepatitis C remains challenging, particularly in resource-limited settings with limited access to molecular testing.
Does the RT-LAMP-coupled CRISPR-Cas12 assay accurately detect HCV RNA compared to the reference method in clinical samples?
Does the RT-LAMP-coupled CRISPR-Cas12 assay accurately detect HCV RNA compared to the reference method in clinical samples?
The RT-LAMP-coupled CRISPR-Cas12 assay provides a highly sensitive and specific point-of-care test for rapid HCV detection in resource-limited settings.
Answers are grounded in this paper and cite their sources.
May enable point-of-care HCV RNA testing where molecular assays are unavailable; leaves open need for field validation before clinical adoption.
Hepatitis C virus (HCV) infection can be cured with pan-genotypic direct-acting antiviral agents. However, identifying individuals with current hepatitis C remains a major challenge, especially in resource-limited settings where access to or availability of molecular tests is still limited. The goal of this study was to develop and validate a molecular assay for the rapid detection of HCV RNA in resource-limited settings. It is based on a combination of reverse transcription loop-mediated isothermal amplification (RT-LAMP) with the clustered regularly interspaced short palindromic repeats–CRISPR-associated protein 12a (CRISPR–Cas12a) cleavage assay that allows the recognition of specific HCV nucleic acid sequences. Amplified products after the cleavage reactions can be visualized on lateral flow strips or measured with a fluorescence detector. When tested on clinical samples from individuals infected with HCV, HIV, or HBV, or from healthy donors, the RT-LAMP-coupled CRISPR–Cas12 assay yielded 96% sensitivity, 100% specificity, and 97% agreement as compared to the reference method (Roche COBAS AmpliPrep/COBAS TaqMan HCV Test). This assay could detect HCV RNA concentrations as low as 10 ng/µL (an estimated 2.38 Log10 IU/mL). Therefore, this sensitive and specific assay may represent an affordable and reliable point-of-care test for the identification of individuals with active hepatitis C in low-resource settings.
No takes yet. Share an insight, caveat, or question.
Kham-Kjing et al. (2022) studied Hepatitis C virus (HCV) infection. RT-LAMP-coupled CRISPR–Cas12 assay vs. Roche COBAS AmpliPrep/COBAS TaqMan HCV Test was evaluated on Diagnostic sensitivity, specificity, and agreement for HCV RNA detection. The RT-LAMP-coupled CRISPR–Cas12 assay yielded 96% sensitivity, 100% specificity, and 97% agreement for HCV RNA detection compared to the reference method.
Synapse has enriched 10 related papers. Consider them for comparative context: